ibuprofen has been researched along with Bronchopulmonary Dysplasia in 17 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Bronchopulmonary Dysplasia: A chronic lung disease developed after OXYGEN INHALATION THERAPY or mechanical ventilation (VENTILATION, MECHANICAL) usually occurring in certain premature infants (INFANT, PREMATURE) or newborn infants with respiratory distress syndrome (RESPIRATORY DISTRESS SYNDROME, NEWBORN). Histologically, it is characterized by the unusual abnormalities of the bronchioles, such as METAPLASIA, decrease in alveolar number, and formation of CYSTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 7.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "Expectant management for PDA in extremely premature infants was noninferior to early ibuprofen treatment with respect to necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks' postmenstrual age." | 5.69 | Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. ( Avino, D; de Baat, T; De Bisschop, B; de Boode, WP; de Vries, WB; Derriks, F; Dijk, PH; Dijkman, KP; Donders, R; Henriksen, TB; Hocq, C; Hundscheid, T; Kooi, EMW; Kroon, AA; Kyng, KJ; Meeus, M; Mulder, AL; Mulder-de Tollenaer, SM; Nuytemans, DHGM; Onland, W; van Kaam, AH; Van Overmeire, B; Vijlbrief, DC; Villamor, E; Visser, R; Zecic, A, 2023) |
| "We investigated the effect of ibuprofen on angiogenesis in human umbilical cord vein endothelial cells (HUVECs) and the therapeutic potential of daily treatment with 50 mg/kg of ibuprofen injected subcutaneously in neonatal Wistar rat pups with severe hyperoxia-induced experimental BPD." | 4.31 | Vascular and pulmonary effects of ibuprofen on neonatal lung development. ( Chen, X; Han, D; Huang, X; Huang, Z; Liu, Y; Wagenaar, GTM; Walther, FJ; Wang, X; Yang, C; Zhong, J, 2023) |
| "To evaluate the association of ibuprofen exposure with the risk of bronchopulmonary dysplasia (BPD) in extremely premature infants." | 3.96 | Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. ( Chen, X; Huang, Z; Lin, Y; Qiu, X; Sun, P; Walther, FJ; Yang, C, 2020) |
| "Treatment of a patent ductus arteriosus with COX-inhibitors such as indomethacin and ibuprofen, increases the risk for bronchopulmonary dysplasia without reducing other complications or death." | 3.75 | [Patent ductus arteriosus in premature infants]. ( Bratlid, D; Farstad, T, 2009) |
| "The question of whether to treat patent ductus arteriosus (PDA) early or wait until symptoms appear remains high on the research agenda for neonatal medicine." | 3.01 | Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. ( Bell, JL; Edwards, C; Field, D; Gupta, S; Hardy, P; Hutchison, E; Johnson, S; Juszczak, E; Kelsall, W; Laube, M; Linsell, L; Pepperell, J; Roberts, T; Sinha, S; Stanbury, K; Subhedar, N; Wyllie, J, 2021) |
| "The patency of the ductus arteriosus is very common in extremely premature infants." | 2.53 | Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes. ( Bancalari, E, 2016) |
| "Although the frequency of secondary patent ductus arteriosus (PDA) ligation and the incidence of bronchopulmonary dysplasia (BPD) was higher in the clinical symptoms group in the univariate analysis, after multivariate logistic regression analysis adjusting for the CRIB-II score, birthweight, birth year, and the invasive ventilator care ≤ 2 postnatal days, there were no significant differences in mortality, frequency of secondary ligation and in-hospital outcomes including necrotizing enterocolitis (NEC), intraventricular hemorrhage (IVH), BPD or death." | 1.46 | Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment. ( Choi, CW; Jung, YH; Kim, BI; Kim, EK; Kim, HS; Lee, JA; Oh, S; Shin, SH; Sohn, JA; Yoo, H, 2017) |
| "The optimal timing of pharmacological treatment for patent ductus arteriosus (PDA) in extremely preterm infants is unknown." | 1.42 | Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants. ( Bonamy, AK; Gudmundsdottir, A; Håkansson, S; Johansson, S; Källen, K; Norman, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Hundscheid, T | 2 |
| Onland, W | 2 |
| Kooi, EMW | 2 |
| Vijlbrief, DC | 2 |
| de Vries, WB | 2 |
| Dijkman, KP | 2 |
| van Kaam, AH | 2 |
| Villamor, E | 2 |
| Kroon, AA | 2 |
| Visser, R | 2 |
| Mulder-de Tollenaer, SM | 2 |
| De Bisschop, B | 2 |
| Dijk, PH | 2 |
| Avino, D | 2 |
| Hocq, C | 2 |
| Zecic, A | 2 |
| Meeus, M | 2 |
| de Baat, T | 2 |
| Derriks, F | 2 |
| Henriksen, TB | 2 |
| Kyng, KJ | 2 |
| Donders, R | 2 |
| Nuytemans, DHGM | 2 |
| Van Overmeire, B | 2 |
| Mulder, AL | 2 |
| de Boode, WP | 2 |
| Chen, X | 2 |
| Han, D | 1 |
| Wang, X | 1 |
| Huang, X | 1 |
| Huang, Z | 2 |
| Liu, Y | 2 |
| Zhong, J | 1 |
| Walther, FJ | 2 |
| Yang, C | 2 |
| Wagenaar, GTM | 1 |
| Qiu, X | 1 |
| Sun, P | 1 |
| Lin, Y | 1 |
| Gupta, S | 2 |
| Juszczak, E | 2 |
| Hardy, P | 2 |
| Subhedar, N | 1 |
| Wyllie, J | 1 |
| Kelsall, W | 1 |
| Sinha, S | 1 |
| Johnson, S | 1 |
| Roberts, T | 1 |
| Hutchison, E | 1 |
| Pepperell, J | 1 |
| Linsell, L | 2 |
| Bell, JL | 2 |
| Stanbury, K | 1 |
| Laube, M | 1 |
| Edwards, C | 1 |
| Field, D | 1 |
| Clyman, RI | 1 |
| Chan, NM | 1 |
| Law, CW | 1 |
| Kwan, KF | 1 |
| Gudmundsdottir, A | 2 |
| Johansson, S | 2 |
| Håkansson, S | 2 |
| Norman, M | 2 |
| Källen, K | 2 |
| Bonamy, AK | 2 |
| Meyer, S | 1 |
| Olsson, KW | 1 |
| Sindelar, R | 1 |
| Lu, D | 1 |
| Tong, X | 1 |
| Haw, MP | 1 |
| Bancalari, E | 1 |
| Yoo, H | 1 |
| Lee, JA | 1 |
| Oh, S | 1 |
| Jung, YH | 1 |
| Sohn, JA | 1 |
| Shin, SH | 1 |
| Choi, CW | 1 |
| Kim, EK | 1 |
| Kim, HS | 1 |
| Kim, BI | 1 |
| Bratlid, D | 1 |
| Farstad, T | 1 |
| Adamska, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)[NCT02884219] | 273 participants (Actual) | Interventional | 2016-12-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for ibuprofen and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.
Topics: Animals; Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Disease Models, Animal; Ductus Arter | 2013 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Patent Ductus Arteriosus and Short- and Long-Term Respiratory Outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Hemodynamics; Humans; Ibuprofen; Indomethacin | 2016 |
[Ibuprofen--a new application for pharmacological closure of patent ductus arteriosus in preterm infants. Preliminary report].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Clinical Trials as Topic; Ductu | 2000 |
3 trials available for ibuprofen and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Echocardiography; Enterocolitis, Necrotizing; | 2023 |
Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Low Birth | 2021 |
Baby-OSCAR: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies-a statistical analysis plan for short-term outcomes.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Ibuprofen; Infant; Infant, Extremely | 2021 |
10 other studies available for ibuprofen and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Vascular and pulmonary effects of ibuprofen on neonatal lung development.
Topics: Animals; Animals, Newborn; Bronchopulmonary Dysplasia; Endothelial Cells; Humans; Hyperoxia; Ibuprof | 2023 |
Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia; Confounding Facto | 2020 |
Ibuprofen versus indomethacin treatment of patent ductus arteriosus: comparative effectiveness and complications.
Topics: Bronchopulmonary Dysplasia; Creatinine; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indome | 2014 |
Timing of pharmacological treatment for patent ductus arteriosus and risk of secondary surgery, death or bronchopulmonary dysplasia: a population-based cohort study of extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fe | 2015 |
The importance of echocardiography and an individual approach to patent ductus arteriosus treatment in extremely preterm infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Adequate timely treatment of patent ductus arteriosus in extremely low birth weight infants: an ongoing challenge.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
Future Benefits of Sequential Echocardiography: Unmasking the Indications for Treatment of Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ib | 2015 |
[Clinical characteristics and cardiac hemodynamic changes of patent ductus ateriosus in preterm infants].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Cardiac Output; Cyclooxygenase Inhibitors; Ductus Arterios | 2015 |
Comparison of the Mortality and In-Hospital Outcomes of Preterm Infants Treated with Ibuprofen for Patent Ductus Arteriosus with or without Clinical Symptoms Attributable to the Patent Ductus Arteriosus at the Time of Ibuprofen Treatment.
Topics: Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Echocardiography; Entero | 2017 |
[Patent ductus arteriosus in premature infants].
Topics: Bronchopulmonary Dysplasia; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Hemodynamics; Huma | 2009 |